Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12106
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Yen Ying | - |
dc.contributor.author | Maruff, Paul | - |
dc.contributor.author | Pietrzak, Robert H | - |
dc.contributor.author | Ellis, Kathryn A | - |
dc.contributor.author | Darby, David G | - |
dc.contributor.author | Ames, David | - |
dc.contributor.author | Harrington, Karra | - |
dc.contributor.author | Martins, Ralph N | - |
dc.contributor.author | Masters, Colin L | - |
dc.contributor.author | Szoeke, Cassandra | - |
dc.contributor.author | Savage, Greg | - |
dc.contributor.author | Villemagne, Victor L | - |
dc.contributor.author | Rowe, Christopher C | - |
dc.date.accessioned | 2015-05-16T01:45:15Z | |
dc.date.available | 2015-05-16T01:45:15Z | |
dc.date.issued | 2014-02-28 | - |
dc.identifier.citation | Alzheimer's & Dementia : the Journal of the Alzheimer's Association 2014; 10(6): 743-751.e1 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/12106 | en |
dc.description.abstract | High β-amyloid (Aβ) is associated with faster memory decline in healthy individuals and adults with mild cognitive impairment (MCI). However, longer prospective studies are required to determine if Aβ-related memory decline continues and whether it is associated with increased rate of disease progression.Healthy controls (HCs; n = 177) and adults with MCI (n = 48) underwent neuroimaging for Aβ and cognitive assessment at baseline. Cognition was reassessed 18 and 36 months later.Compared with low-Aβ HCs, high-Aβ HC and MCI groups showed moderate decline in episodic and working memory over 36 months. Those with MCI with low Aβ did not show any cognitive decline. Rates of disease progression were increased in the high-Aβ HC and MCI groups.In healthy individuals, high Aβ likely indicates that Alzheimer's disease (AD)-related neurodegeneration has begun. Once commenced, the rate of decline in cognitive function remains constant across the preclinical and prodromal stages of AD. | en |
dc.language.iso | en | en |
dc.subject.other | Aβ | en |
dc.subject.other | Cognitive decline | en |
dc.subject.other | Neuropsychology | en |
dc.subject.other | Preclinical AD | en |
dc.subject.other | Prodromal AD | en |
dc.title | Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Alzheimer's & dementia : the journal of the Alzheimer's Association | en |
dc.identifier.affiliation | CogState Ltd., Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | National Ageing Research Institute, Parkville, Victoria, Australia | en |
dc.identifier.affiliation | Department of Psychology and ARC Centre of Excellence in Cognition and Its Disorders, Macquarie University, Sydney, New South Wales, Australia | en |
dc.identifier.affiliation | Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA | en |
dc.identifier.affiliation | Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Kew, Victoria, Australia | en |
dc.identifier.affiliation | Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia | en |
dc.identifier.affiliation | The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia | en |
dc.identifier.affiliation | CSIRO Preventative Health Flagship, Parkville, Victoria, Australia | en |
dc.identifier.affiliation | Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical, and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia | en |
dc.identifier.doi | 10.1016/j.jalz.2013.11.005 | en |
dc.description.pages | 743-751.e1 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/24589436 | en |
dc.contributor.corpauthor | AIBL Research Group | en |
dc.type.content | Text | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Masters, Colin L | |
item.grantfulltext | none | - |
item.openairetype | Journal Article | - |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | The Florey Institute of Neuroscience and Mental Health | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.